Currentsierra health and lifePolicy 2026T0521Z

Noncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds

This policy governs coverage determinations for noncontact normothermic wound warming (NNWT), low-frequency (including noncontact) ultrasound therapy, and real-time fluorescence wound imaging for bacterial detection under UnitedHealthcare Commercial and Individual Exchange plans.

Policy Summary

Payersierra health and life

PolicyNoncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds

Policy CodePolicy 2026T0521Z

Change TypeTemplate updateno material clinical changes

Effective DateJan 1, 2026

Next Review Date

Key ActionVerify member-specific benefit plan and prior authorization requirements before billing; include wound type, baseline measurements, device/frequency, and fluorescence findings in documentation when used.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3technologies addressed

0598T,0599TFluorescence CPT codes listed

multipleevidence sources

insufficientcoverage stance

01/01/2026

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determinations

General Coverage Stance

Covered when ALL of the following are met

policy_stance: Warming therapy (noncontact normothermic wound therapy, NNWT) and low-frequency ultrasound therapies are considered unproven and not medically necessary for treating wounds due to insufficient evidence of efficacy. Noncontact real-time fluorescence wound imaging for bacterial presence is unproven and not medically necessary due to insufficient evidence of safety and/or efficacy.

Direct policy coverage rationale.

Adjunct therapy evidence synthesis

Evidence summary and implications for coverage decisions

NLFU/USSD evidence: Randomized and observational studies show mixed results: small RCTs and retrospective series report wound-area reductions and some faster healing when noncontact low-frequency ultrasound (NLFU) is applied multiple times per week (Beheshti 2014; White 2016; Wagner-Cox 2017; Yao 2014), but a larger multicenter RCT of weekly low-dose high-frequency ultrasound found no benefit and more adverse events (Watson 2011).

Studies limited by small sample sizes, heterogenous devices/frequencies, short follow-up, and variable blinding.

Ultrasound-supported surgical debridement (USSD) meta-analysis: A 2023 meta-analysis of USSD in diabetic foot ulcers reported higher odds of healing for USSD versus standard care (OR 3.08; 95% CI 1.94–4.88), but included studies were generally small and at risk of selection bias, indicating the need for larger, well-designed trials before broad coverage changes.

Meta-analysis findings are promising but limited by the size and quality of included studies.

Fluorescence imaging diagnostic performance: Prospective studies demonstrate high sensitivity and improved detection of moderate-to-heavy bacterial loads with autofluorescence imaging versus clinical signs/symptoms alone (e.g., CSS missed ~85% of loads >10^4 CFU/g in one study; sensitivities reported in pilots 84%–92.6%, accuracy up to ~95% in select series).detection approx >=10^4 CFU/g

Device limitations include limited excitation depth (~1.5 mm) and inability to detect some non-porphyrin-producing organisms; clinical outcome benefits remain incompletely demonstrated.

Clinical utility of fluorescence-guided interventions: Small RCTs and cohort studies (e.g., Rahma 2022 and other pilot trials) suggest fluorescence-guided debridement and targeted management may improve short-term wound-area reduction and increase 12-week healing proportions in underpowered studies, but evidence is not yet definitive for consistent patient-centered outcome improvement across larger populations.

Larger randomized trials are recommended to confirm clinical effectiveness and impact on outcomes such as healing time and antibiotic stewardship.

Adjunctive use criteria

Use of autofluorescence imaging may be considered when used as an adjunct to standard wound assessment to detect moderate-to-heavy bacterial burden; evidence supports improved diagnostic sensitivity but not definitive patient-centered outcome benefit.

Adjunctive diagnostic use: Fluorescence imaging (autofluorescence devices) may be used only as an adjunct to standard clinical assessment (e.g., IWII, NERDS/STONEES checklists) to identify areas of moderate-to-heavy bacterial burden and to guide targeted sampling or debridement.presence of red/cyan fluorescence indicating moderate-to-heavy bacterial load (detects bacteria starting at ~10^4 CFU/g)

Studies show improved sensitivity and accuracy versus clinical signs/symptoms alone, but limitations include shallow excitation depth (~1.5 mm) and inability to detect some non-porphyrin-producing bacteria; fluorescence imaging should not replace standard care or be the sole justification for major therapeutic changes given inconclusive evidence for improved patient-centered outcomes.

The policy considers noncontact normothermic wound therapy (NNWT), low-frequency ultrasound, and real-time fluorescence wound imaging to be not medically necessary (excluded from coverage) because the available evidence is insufficient to demonstrate safety and efficacy for treating wounds.

Fluorescence imaging has known technical limitations: it has a limited excitation depth (approximately 1.5 mm) and cannot detect non-porphyrin-producing bacteria such as Streptococcus, Enterococcus, and Finegoldia. These constraints limit the test's sensitivity for deep infections and for organisms that do not produce porphyrin fluorescence; consequently, clinical utility for some infection scenarios is restricted.

There is insufficient evidence that use of the MolecuLight i:X alone produces improved patient-centered outcomes. Evidence assessments conclude the device may improve detection of high bacterial loads but do not demonstrate consistent improvements in wound healing, quality of life, or other patient-centered endpoints; therefore it should not replace standard clinical assessment or be used as the sole justification for major changes in therapy.

Coverage determinations are governed by the member's specific benefit plan document. If the member-specific plan differs from this policy, the member specific benefit plan terms prevail and may exclude coverage even where this policy discusses coverage considerations.

Warming therapy (NNWT) and low-frequency ultrasound remain unproven and not medically necessary for wound treatment based on current evidence. Noncontact real-time fluorescence imaging is likewise considered unproven for demonstrating clinical outcome benefit; technical limits (e.g., detection depth and organism coverage) further constrain its demonstrated therapeutic value.

A large multicenter randomized trial of weekly low-dose, high-frequency therapeutic ultrasound added to standard care for hard-to-heal venous leg ulcers found no increase in ulcer healing rates, no improvement in quality of life, and a higher rate of adverse events in the ultrasound group; routine coverage for that weekly ultrasound protocol is therefore not supported.

Routine use of fluorescence imaging to claim improved wound closure times or to justify antibiotic stewardship strategies is not supported by the current evidence base. Evidence reviews conclude that while fluorescence imaging can improve detection of wounds with high bacterial loads, there is insufficient evidence that routine fluorescence-guided practice results in better patient-centered outcomes.

Coding and Billing References

Fluorescence imaging (Category III) CPT codesCPT

0598T	Real-time fluorescence wound imaging with clinical darkness, to identify location of bacterial wound pathogens and measure wound size, per session; first anatomic site (e.g., lower extremity, right leg)
0599T	Real-time fluorescence wound imaging with clinical darkness, to identify location of bacterial wound pathogens and measure wound size, per session; each additional anatomic site (e.g., upper extremity, left leg) (List separately in addition to code for primary procedure)

Procedure codes referencedCPT

97610

Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day

Warming therapy supplies and device HCPCS codesHCPCS

A6000	Noncontact wound-warming wound cover for use with the noncontact wound- warming device and warming card
E0231	Noncontact wound-warming device (temperature control unit, AC adapter and power cord) for use with warming card and wound cover
E0232	Warming card for use with the noncontact wound warming device and noncontact wound warming- wound cover

Regulatory clearance referencesmixed

510(k)

FDA clearance pathway reference for MolecuLight i:X and other devices

Applicable CPT codes updatedCPT

0598T	description revised per policy history
0599T	description revised per policy history

Prior authorization affected codesmixed

affected codes

placeholder for codes affected by prior authorization note

inv-17: Fluorescence detection threshold

Detection limitFluorescence imaging detects bacterial presence beginning at approximately 1 x 10^4 CFU/g in tissue (some microbiology references and study thresholds also report 1 x 10^5 CFU/g as a relevant laboratory threshold)

Clinical performance rangeStudies report fluorescence sensitivity and accuracy across loads from 10^4 to 10^9 CFU/g, with peak sensitivity at higher loads (e.g., up to 92.6% at >10^8 CFU/g)

Depth and organism limitationsDevice excitation/detection depth is limited (~1.5 mm) and does not detect non-porphyrin-producing bacteria (e.g., Streptococcus, Enterococcus, Finegoldia)

Implication for samplingFluorescence can identify surface and peri-wound high-load areas to guide targeted sampling or debridement rather than replace microbiology

Provider Responsibilities, Prior Authorization & Documentation

Billing Rule

Code listing and verification

The following lists of procedure, supply, and HCPCS codes are provided for reference only and must be verified prior to billing. Inclusion of a code does not imply coverage or payment. Providers should confirm the applicable code set and modifier usage with the payer and the member specific benefit plan.

Common reference codes: 0598T (real-time fluorescence wound imaging, first anatomic site), 0599T (each additional anatomic site); 97610 (non-contact low-frequency ultrasound, per day); A6000 (noncontact wound-warming wound cover); E0231 (noncontact wound-warming device); E0232 (warming card).
Listing of codes is not exhaustive — check current CPT/HCPCS manuals and payer billing guides before submission.

Prior Authorization

Prior authorization: check member-specific plan

Prior authorization requirements vary by member and plan. Before scheduling or performing adjunctive ultrasound, warming therapy, or fluorescence imaging, check the member specific benefit plan and obtain any required prior authorization.

Background and Scope

Noncontact normothermic wound therapy (NNWT) delivers radiant heat to the wound via a warming unit and a noncontact wound cover while maintaining a humid microenvironment. The intended physiologic effects are to raise wound temperature and improve perfusion and oxygenation, but current clinical evidence does not demonstrate sufficient improvement in wound healing outcomes to support coverage.

Definitions

inv-36: Noncontact normothermic wound therapy (NNWT) — definition summary

DefinitionNoncontact normothermic wound therapy (NNWT) uses a noncontact wound cover plus a warming unit to apply radiant heat and maintain near‑100% relative humidity to raise wound temperature, increase blood flow and oxygenation

PurposeIntended to improve perfusion and promote wound healing by external warming and humidification of the wound microenvironment

ComponentsTypical system includes a warming unit, wound cover, and warming card or consumable wound covers

inv-37: Low-frequency ultrasound (MIST Therapy / NLFU) — definition summary

DefinitionLow‑frequency ultrasound (MIST Therapy / NLFU) is a noncontact ultrasonic therapy delivered via a saline mist from a handheld transducer (approximately 40 kHz for MIST) that cleanses and debrides the wound surface while delivering low‑level ultrasonic energy

Policy History

01/01/2026policy_revisionLatest

Template update and creation of a shared policy version to support application to Oxford plan membership; archived prior versions and updated supporting information.

01/01/2026coding_updateLatest

Updated list of applicable CPT codes to reflect annual edits and revised descriptions for 0598T and 0599T.

Policy Summary

Payersierra health and life

PolicyNoncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds

Policy CodePolicy 2026T0521Z

Change TypeTemplate updateno material clinical changes

Effective DateJan 1, 2026

Next Review Date

SourceLink

On This Page

inv-18: Bacterial load threshold

Clinically meaningful threshold> 1 x 10^4 CFU/g is associated with clinically meaningful bacterial burden (chronic inhibitory bacterial load) and is a target range for fluorescence detection to flag moderate-to-heavy bacterial loads)

Prevalence at thresholdIn a DFU cohort, 93.9% of wounds had loads >10^4 CFU/g when bacterial presence was confirmed by quantitative tissue culture

Diagnostic advantageFluorescence imaging increases sensitivity for detection across the 10^4–10^9 CFU/g range compared with clinical signs alone

Providers must verify prior authorization at the member level — this policy does not replace plan-level requirements.
Where prior authorization is required, document the medical necessity and include the wound history, prior therapies, and rationale for adjunctive device use.

Denial Risk

Risk of Denial for Weekly Ultrasound

Clinical trial evidence does not support weekly low‑dose, high‑frequency ultrasound as improving healing rates, quality of life, or reducing recurrence compared with standard care. Use of weekly ultrasound may result in claim denials if documentation does not justify deviation from standard care.

Risk of denial is higher for weekly administration protocols lacking documentation of prior standard-of-care optimization and clinical rationale.
If using weekly ultrasound therapy, include documentation of prior treatments, clinical indications for frequency, and expected benefit to support medical necessity.

Billing Rule

Coding and documentation note

Document fully to support coding and billing. Include device type, session dates, anatomic site(s), and any supply items used. Lists of codes in this policy are for reference and do not guarantee reimbursement.

Record the specific device or product used (e.g., MolecuLight i:X, MIST Therapy, Warm‑Up).
Report the primary procedure code and any appropriate add‑on or supply HCPCS/CPT codes with correct modifiers and units.
Retain and submit supporting clinical documentation when requested during claims review.

Documentation Required